India, July 7 : Omnigel, Cipla Health’s pain relief brand, has announced the launch of Omnigel Maxstrong, its latest offering in the pain relief segment.
The launch marks Omnigel’s entry into the evolving 2% diclofenac category, which is increasingly being adopted across the industry as an advanced formulation for pain management.
Omnigel Maxstrong is designed for individuals who deal with muscle and joint pain more often than usual, especially as part of active, everyday routines. The formulation is aimed at providing 5X Action and long lasting relief, making it easier to go about daily activities with consistency.
The launch also marks a key milestone for the brand, with Omnigel introducing its first sub-brand along with a distinctive packaging design. The new look reflects a more contemporary and premium identity, while retaining recognisable elements such as the brand’s red palette and core pain relief cues to ensure continuity with its existing equity.
Omnigel Maxstrong will be available in gel (30 gm) and spray formats (35 gm, 55 gm, 75 gm and 100 gm), expanding the brand’s portfolio across multiple formats to cater to varying consumer preferences.
Omnigel continues to build on its core promise of enabling effective pain management, with solutions aimed at supporting sustained movement in everyday life.